Home / Pharmaceuticals / Cancer Diagnostics Market By Test Type (Digital Pathology, Genomic Testing, Cancer Biomarker Tests, Imaging, Endoscopy, Biopsy, Others), By Disease Condition (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Other Cancers) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Cancer Diagnostics Market By Test Type (Digital Pathology, Genomic Testing, Cancer Biomarker Tests, Imaging, Endoscopy, Biopsy, Others), By Disease Condition (Breast Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Colorectal Cancer, Ovarian Cancer, Liver Cancer, Other Cancers) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Oct 2018 | Report Code: 59371-10-18

Industry Outlook

The global cancer diagnostics market to reach US$ 115.3 Bn in 2026 growing at compound annual growth rate (CAGR) of 6.1% during the forecast period from 2018 to 2026. The prime factors driving the global cancer diagnostics market is the rising prevalence of cancer worldwide. As per the World Health Organization (WHO), cancer accounted for the second leading cause of mortality, claiming to 8.8 million deaths in 2015 globally. The National Cancer Institute estimated around 1,685,210 new cancer cases in 2016 in the United States. As per the Centers for Disease Control and Prevention (CDC), cancer cases anticipated to increase by 2 million each year by 2020. Such continuous rise in prevalence of cancer would propel the demand for cancer diagnostics ensuring persistent remunerative growth across the forecast period. Advancements in omics technologies, imaging techniques, surge in government funding for cancer research, growing healthcare expenditure and demand for personalized medicines would further propel cancer diagnostics market during the forecast period. Development in genomics and next generation sequencing technique have revolutionized cancer diagnostics and cancer management by analysing multiple biomarker and mutations for early cancer treatment regimes. Development in radiology techniques also known radiomics have benefitting effects of cancer diagnostics market. For instance, radiological imaging are non-invasive in nature and provides 3D picture of solid tumor unlike conventional biopsies and can be performed multiple time with any adverse effects on the body. Development of technologically advanced mammography, PET and SPECT scan, and other imaging modalities for cancer detection have positively impacted the cancer detection accuracy and projected to contribute substantial market revenue during the forecast period.

Market Synopsis

Cancer Diagnostics Market

Advent of Cancer Biomarker Technique to Drive the Market during the Forecast Period

In 2017, imaging segment held the largest share in the global cancer diagnostics market. Imaging techniques are the usually the first type of test carried out for any cancer diagnostics along with number of genomics and laboratory tests. Advancements in the medical devices market space have positively impacted the growth of imaging segment in cancer diagnostics owing to accurate results, better tumor outlook, non-invasiveness and quick solutions. Biomarkers have proved fruitful for diagnosis, monitoring and predicting the therapeutic treatment and its efficacy. For instance, the widespread application of prostate specific antigen (PSA) and BRCA gene in the screening of prostate cancer and breast cancer respectively have led to the discovery studies for different types of cancer as well. For example, in the near future a serum or urine test may derive clinical decisions in every phase of cancer. Thus complementing and substituting the current invasive techniques.

Cancer Diagnostics Market

North America Held Lion’s Share in Cancer Diagnostics Market

North America being the spearhead in the cancer research have emerged as the leading market in cancer diagnostics market, while Asia Pacific is heading towards being the hub for oncology research due to growing contract research organizations and increased investments from industry giants. Hence, Asia Pacific is projected to proliferate rapidly during the forecast period. Huge investment by government research institutes in discovery of novel cancer diagnostic techniques have boosted the growth in various cancer detection techniques. U.S. have highly supported the development of novel cancer biomarker tests due to its accuracy in early detection of cancer. For instance, Mammaprint is a gene expression-based biomarker that predicts the recurrence of breast cancer after chemotherapy. Asia Pacific is holds a high potential in the cancer diagnostics market due to high target population in the region. Developing healthcare infrastructure, availability of sophisticated imaging center in Japan, China, Australia and India will further drive the market in the region.

Cancer Diagnostics Market

Historical & Forecast Period

2016 – Historical Year

2017 – Base Year

2018-2026 – Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments calculated for the forecast period from 2018 to 2026.

Cancer Diagnostics Market

Report Scope by Segments

Cancer Diagnostics market report furnishes quantitative analysis along with its latest market trends. The market is segmented based on test type, disease condition, and geography.

By Test Type (2016–2026; US$ Bn)

  • Digital Pathology
  • Genomic Testing
  • Cancer Biomarker Tests
  • Circulating Tumor Cells (CTC) Tests
  • Prostate Specific Antigen Tests
  • Alpha-Fetoprotein (AFP) Test
  • Cancer Antigen Tests (CA 19-9 Test, CA 125 Test)
  • EGFR Mutation Tests
  • HER2 Test
  • BRCA Test
  • Others (KRAS Mutation Tests, ALK Test and CEA Tests)
  • Imaging
  • Positron Emission Tomography (PET) Scan
  • Magnetic Resonance Imaging (MRI) Scan
  • Computed Tomography (CT) Scan
  • Mammography
  • Ultrasound
  • Endoscopy
  • Biopsy
  • Others (Barium Enema, Bone Scan)

By Disease Condition (2016–2026; US$ Bn)

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Blood Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Liver Cancer
  • Other Cancers (Skin Cancer, Kidney Cancer, Cervical Cancer)

Geography Segment (2016–2026; US$ Bn)

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific (APAC)
    • China
    • Japan
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa (MEA)
    • GCC
    • Rest of Middle East and Africa

Market is studied in order to understand the current dynamics and future trends in the global cancer diagnostics market. The study includes market size and forecast for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rate (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The prominent players operating the global cancer diagnostics market are Abbott Laboratories, Qiagen, F. Hoffman-La Roche, Alere, Inc., GE Healthcare, Siemens Healthineers, Agilent Technologies, among others. The companies are engaging in mergers and acquisitions to maintain competency in the market. In 2017, Abbott Laboratories, Inc., acquired Alere, Inc. to extend its product offering in cancer diagnostics and other point-of-care diagnostics solutions.

Key questions answered in this report

  • How the global cancer diagnostics market will perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the cancer diagnostics market and valuable opportunities for key players?
  • Who are the leading players in the global cancer diagnostics market?
  • Which is the leading/and fastest region in the global cancer diagnostics market?
  • Currently, what are the regulatory structure for the cancer diagnostics?
  • What are drivers and restrains governing the global cancer diagnostics market?
  • What is the future of cancer diagnostics and how it will shape the cancer detection and therapeutic management

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Cancer Diagnostics Market Portraiture
2.2. Global Cancer Diagnostics Market, by Test Type, 2017 (US$ Mn)
2.3. Global Cancer Diagnostics Market, by Disease Condition, 2017 (US$ Mn)
2.4. Global Cancer Diagnostics Market, by Geography, 2017 (US$ Mn)

Chapter 3. Cancer Diagnostics: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Cancer Diagnostics Market, by Key Players, 2017

Chapter 4. Global Cancer Diagnostics Market, by Test Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Digital Pathology
4.3. Genomic Testing
4.4. Cancer Biomarker Tests
4.4.1. Circulating Tumor Cells (CTC) Tests
4.4.2. Prostate Specific Antigen Tests
4.4.3. Alpha-Fetoprotein (AFP) Test
4.4.4. Cancer Antigen Tests (CA 19-9 Test, CA 125 Test)
4.4.5. EGFR Mutation Tests
4.4.6. HER2 Test
4.4.7. BRCA Test
4.4.8. Others (KRAS Mutation Tests, ALK Test and CEA Tests)
4.5. Imaging
4.5.1. Positron Emission Tomography (PET) Scan
4.5.2. Magnetic Resonance Imaging (MRI) Scan
4.5.3. Computed Tomography (CT) Scan
4.5.4. Mammography
4.5.5. Ultrasound
4.6. Endoscopy
4.7. Biopsy
4.8. Others (Barium Enema, Bone Scan)

Chapter 5. Global Cancer Diagnostics Market, by Disease Condition, 2016-2026 (US$ Mn)
5.1. Overview
5.2. Breast Cancer
5.3. Lung Cancer
5.4. Prostate Cancer
5.5. Blood Cancer
5.6. Colorectal Cancer
5.7. Ovarian Cancer
5.8. Liver Cancer
5.9. Other Cancers (Skin Cancer, Kidney Cancer, Cervical Cancer)

Chapter 6. Global Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. North America Cancer Diagnostics Market Analysis, 2016 – 2026
6.1.1. North America Cancer Diagnostics Market, by Test Type, 2016 - 2026 (US$ Mn)
6.1.2. North America Cancer Diagnostics Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.1.3. North America Cancer Diagnostics Market, by Country, 2016 – 2026 (US$ Mn)
6.1.3.1. U.S.
6.1.3.2. Canada
6.2. Europe Cancer Diagnostics Market Analysis, 2016 – 2026
6.2.1. Europe Cancer Diagnostics Market, by Test Type, 2016 - 2026 (US$ Mn)
6.2.2. Europe Cancer Diagnostics Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.2.3. Europe Cancer Diagnostics Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.2.3.1. U.K.
6.2.3.2. Germany
6.2.3.3. Rest of Europe
6.3. Asia Pacific Cancer Diagnostics Market Analysis, 2016 – 2026
6.3.1. Asia Pacific Cancer Diagnostics Market, by Test Type, 2016 - 2026 (US$ Mn)
6.3.2. Asia Pacific Cancer Diagnostics Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.3.3. Asia Pacific Cancer Diagnostics Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.3.3.1. China
6.3.3.2. Japan
6.3.3.3. Rest of Asia Pacific
6.4. Latin America Cancer Diagnostics Market Analysis, 2016 – 2026
6.4.1. Latin America Cancer Diagnostics Market, by Test Type, 2016 - 2026 (US$ Mn)
6.4.2. Latin America Cancer Diagnostics Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.4.3. Latin America Cancer Diagnostics Market, by Country/Region, 2016 – 2026 (US$ Mn)
6.4.3.1. Brazil
6.4.3.2. Mexico
6.4.3.3. Rest of Latin America
6.5. Middle East & Africa Cancer Diagnostics Market, 2016 – 2026
6.5.1. Middle East & Africa Cancer Diagnostics Market, by Test Type, 2016 - 2026 (US$ Mn)
6.5.2. Middle East & Africa Cancer Diagnostics Market, by Disease Condition, 2016 - 2026 (US$ Mn)
6.5.3. Middle East & Africa Cancer Diagnostics Market, by Region, 2016 – 2026 (US$ Mn)
6.5.3.1. GCC
6.5.3.2. Rest of Middle East & Africa

Chapter 7. Company Profiles
7.1. Abbott Laboratories, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Qiagen
7.3. F. Hoffman-La Roche
7.4. Ambry Genetics
7.5. bioMeriux SA
7.6. Becton, Dickinson & Company
7.7. GE Healthcare
7.8. Siemens Healthineers
7.9. Philips Healthcare
7.10. Agilent Technologies, Inc.
7.11. Illumina, Inc.
7.12. Hologic, Inc.

Note:

Modification in the list of company profiles or scope of the study can be incorporated on request.

FIG 1. Cancer Diagnostics Market: Research Methodology
FIG 2. Cancer Diagnostics : Market Segmentation
FIG 3. Global Cancer Diagnostics Market, by Testing Type, 2017 (US$ Mn)
FIG 4. Global Cancer Diagnostics Market, by Disease Condition, 2017 (US$ Mn)
FIG 5. Global Cancer Diagnostics Market, by Geography, 2017 (US$ Mn)
FIG 6. Attractive Investment Proposition, by Geography, 2017
FIG 7. Competitive Analysis: Global Cancer Diagnostics Market, by Key Players, 2017
FIG 8. Global Digital Pathology in Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 9. Global Genomic Testing in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 10. Global Circulating Tumor Cells (CTC) Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 11. Global Prostate Specific Antigen Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 12. Global Alpha-Fetoprotein (AFP) Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 13. Global Cancer Antigen Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 14. Global EGFR Mutation Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 15. Global HER2 Test in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 16. Global BRCA Test in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 17. Global Other Biomarker Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 18. Global Positron Emission Tomography (PET) Scan in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 19. Global Magnetic Resonance Imaging (MRI) Scan in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 20. Global Computed Tomography (CT) Scan in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 21. Global Mammography in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 22. Global Ultrasound in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 23. Global Endoscopy in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 24. Global Other Tests in Cancer Diagnostics Market, 2016-2026(US$ Mn)
FIG 25. Global Cancer Diagnostics Market for Breast Cancer, 2016-2026 (US$ Mn)
FIG 26. Global Cancer Diagnostics Market for Lung Cancer, 2016-2026(US$ Mn)
FIG 27. Global Cancer Diagnostics Market for Prostate Cancer, 2016-2026 (US$ Mn)
FIG 28. Global Cancer Diagnostics Market for Blood Cancer, 2016-2026 (US$ Mn)
FIG 29. Global Cancer Diagnostics Market for Colorectal Cancer, 2016-2026 (US$ Mn)
FIG 30. Global Cancer Diagnostics Market for Ovarian Cancer, 2016-2026 (US$ Mn)
FIG 31. Global Cancer Diagnostics Market for Liver Cancer, 2016-2026 (US$ Mn)
FIG 32. Global Cancer Diagnostics Market for Other Cancer, 2016-2026 (US$ Mn)
FIG 33. U.S. Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 34. Canada Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 35. U.K. Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 36. Germany Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 37. Rest of Europe Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 38. China Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 39. Japan Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 40. Rest of Asia Pacific Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 41. Brazil Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 42. Mexico Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 43. Rest of Latin America Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 44. GCC Cancer Diagnostics Market, 2016-2026 (US$ Mn)
FIG 45. Rest of Middle East & Africa Cancer Diagnostics Market, 2016-2026 (US$ Mn)

TABLE 1 Global Cancer Diagnostics Market Portraiture
TABLE 2 Global Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 3 Global Cancer Biomarker Test Market in Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 4 Global Imaging Market in Cancer Diagnostics Market, by Type, 2016 – 2026 (US$ Mn
TABLE 5 Global Cancer Diagnostics Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 6 Global Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 7 North America Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 8 North America Cancer Diagnostics Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 9 North America Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 10 North America Cancer Diagnostics Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 11 Europe Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 12 Europe Cancer Diagnostics Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 13 Europe Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 14 Europe Cancer Diagnostics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 15 Asia Pacific Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 16 Asia Pacific Cancer Diagnostics Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 17 Asia Pacific Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 18 Asia Pacific Cancer Diagnostics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 19 Latin America Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 20 Latin America Cancer Diagnostics Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 21 Latin America Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 22 Latin America Cancer Diagnostics Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 23 Middle East & Africa Cancer Diagnostics Market, by Test Type, 2016 – 2026 (US$ Mn)
TABLE 24 Middle East & Africa Cancer Diagnostics Market, by Disease Condition, 2016 – 2026 (US$ Mn)
TABLE 25 Middle East & Africa Cancer Diagnostics Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 26 Middle East & Africa Cancer Diagnostics Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 27 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Qiagen: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 F. Hoffman-La Roche: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Ambry Genetics: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 bioMeriux SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 Becton, Dickinson & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 33 GE Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 34 Siemens Healthineers: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 35 Philips Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 36 Agilent Technologies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 37 Illumina, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 38 Hologic, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients